Solutions
Miura Consulting’s ARAN solution is now supporting Fund clients with an automated “plug-and-play” AIFMD submission service.
ARAN was designed to eliminate the complexity and resource intensity of completing a manual submission and to reduce the cost of implementing an automated solution.
The Alternative Investment Fund Management Directive (AIFMD) is the latest stringent regulatory reporting requirement, aimed to deliver transparency to the hedge fund and asset management industries. As many Hedge funds are completing their first fund submission this month, Miura has been working with the industry to provide a comprehensive but efficient solution, which quickly imports and maps fund administration
Insurers in Asia and Europe are being guided by the shadow of local regulations, as well as investment logic, in their allocating to alternative strategies.
While their plans are often to boost exposure to non-traditional asset classes, the degree of such increases will often hinge on regulations, according to the inaugural edition of The Cerulli Edge – International Institutional Edition.
In Europe, punitive capital charges on insurers' alternative investments under Solvency II, taking effect from 2016, threaten to limit insurers growing their allocations to non-traditional classes.
In Asia, by contrast, Chinese insurers have used the liberalisation of their investment options
Euro Choice Secondary, the first pure secondary fund advised by Akina, has held its final close at EUR224 million, exceeding its target of EUR200 million.
The fund attracted a high level of interest with ultimately some 35 high quality limited partners subscribing, including public and private pension funds, endowments, insurance companies, family offices and wealthy individuals. Geographies range from Australia, North America and Canada to various European countries.
Christopher S. Bödtker, Managing Partner of Akina, says: “Euro Choice Secondary, the first pure secondary fund investment programme we advise, exceeding its target size makes us very proud and we are thankful
NGP Energy Capital Management (NGP) has held the final closing of NGP Natural Resources XI at its hard cap of USD5.325 billion.
NGP XI will continue NGP’s 26-year history as a premier provider of private capital and sponsorship to the natural resources industry, focusing on the oil and gas production, oilfield services, and energy midstream sectors through its Natural Gas Partners investment platform. NGP XI will be managed by NGP, bringing the cumulative committed capital under management since 1988 to USD16.5 billion.
Kenneth A Hersh, Chief Executive Officer, says: “We are extremely thankful for the ongoing loyalty and support of
Arma Partners has acted as exclusive financial adviser on the sale of Clarion Events Limited to Providence Equity Partners.
Clarion was owned by Veronis Suhler Stevenson and Trilantic Capital Partners, who acquired the company in 2008 and have supported its transformational growth through organic investment and bolt-on acquisitions.
Clarion is one of the world’s leading event organisers. The company employs over 500 staff and operates events in Europe, Latin America, the Middle East and Africa, North America and the Asia Pacific region. Clarion’s events address sectors including Energy, Defence & Security, Gaming, Trade, Consumer, Telecoms, Payments and Life Sciences.
Livingstone’s Consumer sector team has sold Extreme Cool Ltd which owns and operates Chill Factore, a 167,000 sq ft ski slope and activity centre in Manchester, to a joint venture between Development Securities plc and Pemberstone Investments for GBP15.5m.
This is Livingstone’s fifth travel/leisure sector deal in the last 12 months.
Opened in November 2007, the venue incorporates the longest indoor real ski slope in the UK – at 180m – as well as a climbing wall and 16 retail and restaurant units. The venue currently attracts between 1.2 million and 1.4 million visitors per year.
Martin Leppard, Chairman at
Private equity fund American Securities has held the first and final closing of American Securities Partners VII with total capital commitments of USD5 billion.
As a result of strong investor interest, American Securities closed the fund above the USD4 billion target and at the hard cap the firm established at the outset of fundraising in September 2014.
"American Securities greatly appreciates the interest expressed in ASP VII by many long-standing relationships, as well as new investors, from the US and global investing community," says Michael G Fisch, President and CEO of American Securities. "This new partnership provides us with
EnBW has sold 49.89% of the shares in offshore wind farm EnBW Baltic 2 to Australian private equity investor Macquarie Capital.
The purchase agreement for the transaction has now been signed. The purchase price for the shares is EUR 720 million. They will be transferred to Macquarie Capital following antitrust clearance and full commissioning of the offshore wind farm, which is expected next summer. EnBW will operate the wind farm and perform maintenance tasks, resulting in the expansion of its service business.
A team led by lead partner Dr Jochen Lamb advised EnBW on all aspects of the transaction. EnBW
Fountain Healthcare Partners has held the initial closing of its second fund, Fountain Healthcare Partners Fund II, with EUR85 million of committed capital.
The fund is a dedicated life science venture capital (VC) fund and brings Fountain’s total capital under management to EUR158 million. Within the life science sector, Fund II will primarily focus on specialty pharmaceuticals, biotechnology, medical devices and diagnostics.
Fountain will invest over 75% of its capital in Europe with the balance in the US market. Having exceeded its initial close target, Fountain is now seeking additional investors to close Fund II with a hard cap of
Trevi Therapeutics has closed a USD15 million senior secured term loan agreement provided by Solar Capital Ltd (Solar Capital) as collateral agent and lender and Square 1 Bank as lender.
“This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis,” says Jennifer Good, President and CEO.
“Trevi is developing therapeutic alternatives for the relief of severe chronic itch conditions which currently have no approved therapies in the US,” says Anthony Storino, head of healthcare venture lending at Solar Capital. “Solar Capital is pleased
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
